This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Don't Overlook Lilly (LLY) International Revenue Trends While Assessing the Stock
by Zacks Equity Research
Review Lilly's (LLY) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
The Zacks Analyst Blog Highlights Apple, Eli Lilly, Shopify and ImmuCell
by Zacks Equity Research
Apple, Eli Lilly, Shopify and ImmuCell are part of the Zacks top Analyst Blog.
Top Stock Reports for Apple, Eli Lilly & Shopify
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Company (LLY) and Shopify Inc. (SHOP), as well as a micro-cap stock ImmuCell Corporation (ICCC).
LLY Rises More Than 4% in a Week: How to Play the Stock
by Kinjel Shah
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
by Zacks Equity Research
Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year sales.
Should Pfizer Stock Be in Your Portfolio Post a Robust Q4 Performance?
by Kinjel Shah
Investors may stay invested in PFE stock to see how its new growth drivers perform.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Pharma Stock Roundup: PFE, LLY, NVO, LLY and AZN's Q4 Earnings Update
by Kinjel Shah
PFE, LLY, NVO, LLY and AZN announce fourth-quarter earnings.
Stock Market News for Feb 7, 2025
by Zacks Equity Research
U.S. stock markets closed mixed on Thursday after a choppy session.
Compared to Estimates, Lilly (LLY) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Weekly Jobless Claims Exceed Expectations
by Zacks Equity Research
Weekly Jobless Claims Exceed Expectations.
LLY's Q4 Earnings Beat, Mounjaro, Zepbound Sales Fall Shy of Estimates
by Zacks Equity Research
Eli Lilly beats fourth-quarter estimates for earnings and sales. Mounjaro and Zepbound sales miss estimates.
Pre-Markets Higher on Easy Jobless Claims, Q4 Earnings
by Mark Vickery
Last week, +219K Initial Jobless Claims were made -- higher than the slightly upwardly revised +208K.
Eli Lilly (LLY) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of 5.77% and 0.44%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Markets Jump Ahead of the Close; QCOM, F, ARM Beat Estimates After
by Mark Vickery
Qualcomm (QCOM) notched another big beat on its Q1 bottom line, with earnings of $3.41 per share flying past the $2.93 for the Zacks consensus.
AbbVie Rises 8% Since Q4 Earnings: Buy, Hold or Sell the Stock?
by Kinjel Shah
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
NVO Q4 Earnings Beat Estimates, GLP-1 Drugs Boost Sales, Stock Up
by Zacks Equity Research
Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes and Obesity care products.
PFE's Colorectal Cancer Drug Meets Other Dual Primary Goal of PFS
by Zacks Equity Research
Pfizer's late-stage BRAF V600E-mutant mCRC study of the Braftovi combo regimen meets its other dual primary endpoint of PFS with statistical significance.
Merck (MRK) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 1.78% and 0.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
The Zacks Analyst Blog Highlights Merck, Pfizer, Eli Lilly, Amgen and Bristol Myers Squibb
by Zacks Equity Research
Merck, Pfizer, Eli Lilly, Amgen and Bristol Myers Squibb are included in this Analyst Blog.
Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecasts?
by Zacks Equity Research
Let's look at five pharma and drug companies, MRK PFE, LLY, AMGN and BMY, which are scheduled to release their fourth-quarter 2024 results later this week.
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO's fourth-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.